HRS-9813 / Jiangsu Hengrui Pharma - LARVOL DELTA

Study on the Drug Interactions of HRS-9813, Pirfenidone and Nintedanib in Healthy Subjects (clinicaltrials.gov) - P1 | N=20 | Not yet recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd

New P1 trial • Immunology • Pulmonary Disease • Respiratory Diseases

Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Trial to Evaluate the Efficacy and Safety of HRS-9813 in Subjects With Pulmonary Fibrosis (clinicaltrials.gov) - P2 | N=270 | Not yet recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd

New P2 trial • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

A Trial of HRS-9813 Capsule and Tablet in Healthy Subjects (clinicaltrials.gov) - P1 | N=12 | Completed | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | Active, not recruiting ➔ Completed

Trial completion • Immunology • Pulmonary Disease • Respiratory Diseases

A Trial of HRS-9813 Capsule and Tablet in Healthy Subjects (clinicaltrials.gov) - P1 | N=12 | Active, not recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | Recruiting ➔ Active, not recruiting

Enrollment closed • Immunology • Pulmonary Disease • Respiratory Diseases

A Trial of HRS-9813 Capsule and Tablet in Healthy Subjects (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Immunology • Pulmonary Disease • Respiratory Diseases

A Trial of HRS-9813 in Healthy Subjects (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | Not yet recruiting ➔ Recruiting | N=30 ➔ 60 | Trial completion date: Apr 2025 ➔ Jul 2025

Enrollment change • Enrollment open • Trial completion date • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

A Trial of HRS-9813 Capsule and Tablet in Healthy Subjects (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd

New P1 trial • Immunology • Pulmonary Disease • Respiratory Diseases

Hengrui Medicine's innovative drug HRS-9813 capsules for idiopathic pulmonary fibrosis approved for clinical use [Google translation] (Jiangsu Hengrui Press Release) - "Recently, Guangdong Hengrui Medicine Co., Ltd., a subsidiary of Hengrui Medicine, received the 'Notice of Approval for Drug Clinical Trial' approved and issued by the National Medical Products Administration, approving the clinical trial of the Class 1 new drug HRS-9813 capsule for idiopathic pulmonary fibrosis (IPF)."

New trial • Idiopathic Pulmonary Fibrosis

A Trial of HRS-9813 in Healthy Subjects (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd

New P1 trial • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

A Trial of HRS-9813 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=50 | Completed | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | N=74 ➔ 50 | Recruiting ➔ Completed

Enrollment change • Trial completion

A Trial of HRS-9813 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=74 | Recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd | Not yet recruiting ➔ Recruiting

Enrollment open

A Trial of HRS-9813 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=74 | Not yet recruiting | Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd

New P1 trial